A new Fierce Pharma report says the biopharma industry is heading into a more difficult 2026 as major companies confront a mix of patent expirations, slowing growth, and uneven commercial outlooks. The article, published March 13, 2026, says that among the world’s 25 largest biopharma companies, only five expect faster growth in 2026 than in 2025, while some are projecting outright sales declines.
Fierce Pharma highlights Novo Nordisk as one of the more surprising examples, noting that the company expects a significant drop in sales, while other drugmakers are also facing the loss of patent protection for blockbuster products and therefore guiding to slower growth or lower revenue. The same reporting points to an industry mood shift: one year ago, large drugmakers were entering 2025 with strong momentum, but by March 2026, the tone had changed toward caution.
This fits a broader 2026 market narrative. Evaluate says its 2026 preview focuses in part on market shifts, launches, and patent cliffs, while other sector reporting has described 2026 as a year when several blockbuster products will face meaningful loss-of-exclusivity pressure.
At first glance, that may sound like a finance story rather than a pharmacovigilance story. But patent expirations often have real implications for drug safety operations. When major brands lose exclusivity, companies typically face new competitive pressure, changing product mix, more aggressive lifecycle management, and in some cases increased dependence on pipeline assets or differentiated safety positioning. That connection is an inference, but it is a practical one given the commercial pressures described in the 2026 outlook reporting.
For pharmacovigilance teams, tougher market conditions can affect priorities in several ways. First, products nearing or crossing patent expiry may still require robust postmarketing surveillance even as commercial attention shifts elsewhere. Second, companies facing slower top-line growth may become more selective about investment, which makes the efficiency and clarity of safety operations even more important. Third, launch-stage and growth-stage assets may come under increased internal scrutiny because they are expected to offset revenue lost to patent cliffs. Those are logical operational implications of the slowdown and LOE pressures now being discussed across the sector.
The Fierce coverage also places part of the 2026 story in the context of GLP-1 competition, especially the diverging trajectories of Novo Nordisk and Eli Lilly. Fierce says the two companies appear to be moving in opposite directions, with Lilly continuing to benefit from strong momentum while Novo faces a much harder outlook. Separate recent reporting also points to growing concern about Novo’s future positioning as semaglutide approaches patent expiry in some markets and competitive pressure intensifies.
That matters because when companies come under commercial pressure, the value of a strong safety profile becomes even more strategic. In a crowded market, regulators, prescribers, patients, and payers all look closely at risk communication, real-world tolerability, and postmarketing evidence. Pharmacovigilance may not stop a patent from expiring, but it can influence how a product is understood, differentiated, and managed in a more competitive environment. This is an inference, but it follows naturally from the combination of patent-cliff pressure, slowing growth, and intensified rivalry described in the 2026 outlook coverage.
There is also a portfolio-level consequence. As large companies lose exclusivity on older blockbusters, they often rely more heavily on newer launches, label expansions, and adjacent indications to sustain growth. That can increase the importance of early signal detection, benefit-risk communication, and disciplined safety support for products expected to carry more of the commercial load. Evaluate’s 2026 preview explicitly frames the year around launches and market transitions, which supports that interpretation.
For PV leaders, the message is straightforward: 2026 may be a harder year commercially, but that does not make drug safety less important. It may make it more important. In a tougher environment, companies need safety teams that can protect compliance, support product credibility, and generate confidence in both established and growth-driving assets. The patent cliff is a commercial event, but its ripple effects can reach deeply into pharmacovigilance strategy.
Why this matters for PV professionals
Patent expirations are usually discussed in revenue terms, but they also reshape portfolio focus, lifecycle strategy, launch pressure, and the operational importance of safety evidence. For pharmacovigilance teams, a tougher 2026 could mean higher expectations to support both mature products and the next wave of growth assets with sharper, more visible safety intelligence.
0 Comments